publication date: Dec. 19, 2010

In this issue: 

New NCI director proposes $9 million Community Cancer Centers Program.

President appointed John Niederhuber NCI director.

ODAC nixes Abraxane for adjuvant breast cancer, while Genasense falls victim to its randomized trial.

Download (PDF 4.3MB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.